Rabablert J, Yoksan S
Department of Biology, Faculty of Science, Silpakorn University, Nakhon Phatom 73100, Thailand.
Curr Pharm Des. 2009;15(11):1203-11. doi: 10.2174/138161209787846865.
Dengue viruses cause 50-100 million cases of acute febrile disease every year, including more than 500000 reported cases of the severe forms of the disease-dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Attempts to create conventional vaccines have been hampered by the lack of suitable experimental models, the need to provide protection against all four serotypes simultaneously and the possible involvement of virus-specific immune responses in severe disease. Live attenuated D2 16681-PDK53 vaccine was first developed from Mahidol University, Thailand. This vaccine induced both humoral and cell-mediated immunity and lack of reactogeneticity in humans. Infectious cDNA clones of the virulent D2 16681 virus and its attenuated D2 16681-PDK53 were constructed. The attenuated virus elicited neutralizing antibodies in mice and monkeys and developed viremia in monkeys. At molecular level, patterns of cytokines which are immunological mediators released from human mononuclear cells obtained from dengue naïve and immune donors infected with this attenuated virus compared with virulent virus were studied. In dengue naïve PBMC, the virulent and attenuated clones induced alternation in expression of 25 and 24 versus 13 and 18 genes out of 268 genes on day 1 and 3. In dengue immune PBMC, the virulent and attenuated clones induced alternation in expression of 33 and 38 versus 25 and 29 genes on days 1 and 3. Up-regulation of IL-1beta, IL-6, IL-8, IL-10, IFN-alpha, IFNgammaR, MIP-1alpha, MIP-1beta, MIP-2alpha, VEGF and down-regulation of IL-4, IL-4R, IL-RII, MIF, RANTES, IGF-1, GM-CSF-2 were shown. This review pointed out the infectious clones of the attenuated D2 16681-PDK53 was safe and induced both neutralizing antibodies in vivo and cytokine gene expression in vitro at molecular level. Furthermore, the phenotypic markers of ideal dengue vaccine could be included the alteration of cytokine gene expression and cytokine production in human mononuclear cells.
登革病毒每年导致5000万至1亿例急性发热疾病,其中包括超过50万例该疾病的严重形式——登革出血热(DHF)和登革休克综合征(DSS)的报告病例。由于缺乏合适的实验模型、需要同时提供针对所有四种血清型的保护以及病毒特异性免疫反应可能参与严重疾病,研发传统疫苗的尝试受到了阻碍。减毒活D2 16681-PDK53疫苗最初由泰国玛希隆大学研发。这种疫苗在人体中诱导了体液免疫和细胞介导免疫,且无反应原性。构建了强毒D2 16681病毒及其减毒株D2 16681-PDK53的感染性cDNA克隆。减毒病毒在小鼠和猴子中诱导产生中和抗体,并在猴子中引发病毒血症。在分子水平上,研究了从未感染过登革病毒的供体和感染过该减毒病毒的免疫供体获取的人单核细胞释放的免疫介质细胞因子的模式,并与强毒病毒进行了比较。在从未感染过登革病毒的外周血单核细胞(PBMC)中,强毒株和减毒株在第1天和第3天分别诱导268个基因中的25个和24个以及13个和18个基因表达发生变化。在感染过登革病毒的PBMC中,强毒株和减毒株在第1天和第3天分别诱导33个和38个以及